Cefalexin
| Error creating thumbnail: File missing | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Well absorbed |
| Metabolism | 90% excreted unchanged |
| Elimination half-life | 0.9 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H17N3O4S |
| Molar mass | 347.39 g/mol |
|
WikiDoc Resources for Cefalexin |
|
Articles |
|---|
|
Most recent articles on Cefalexin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cefalexin at Clinical Trials.gov Clinical Trials on Cefalexin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cefalexin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cefalexin Discussion groups on Cefalexin Directions to Hospitals Treating Cefalexin Risk calculators and risk factors for Cefalexin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cefalexin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Cefalexin (INN) (IPA: Template:IPA) or cephalexin (USAN) is a first-generation cephalosporin antibiotic. It is an orally-administered agent with a similar antimicrobial spectrum to the intravenous agents cefalotin and cefazolin. It is commonly marketed under the trade name Keflex (Lilly) or Sporidex (Ranbaxy).
Clinical use
Indications
Cefalexin is used to treat urinary tract infections, respiratory tract infections (including sinusitis, otitis media, pharyngitis, tonsillitis and pneumonia), skin and soft tissue infections.
Although it is not generally considered first-line therapy for any indication, it is a useful alternative to penicillins in patients with penicillin hypersensitivity. There is, however, cross-reactivity in 10% of patients with hypersensitivity to penicillins and carbapenems.
Formulations
Cefalexin is commonly marketed as tablets(250 mg and 500 mg), tablets, and powder for oral suspension (125 mg/5 mL and 250 mg/5 mL).
Cephalexin is being marketed as Keflex® 750 mg as "taken twice per day". The advantage of Keflex 750 is that it provides the same total daily dose most health care professionals prescribe with only two capsules per day. By making Keflex 750 convenient for patients, compliance may be improved with this new dosing option. Keflex 750 is covered by most major insurers with an average copay of between $20 and $25. Retail price is approximately $45 for a 20 capsule supply.
It is marketed by generic pharmaceutical manufacturers under a wide range of brand names, including: Apo-Cephalex, Biocef, Cefanox, Ceporex, Cephabos, Cilex, Ialex, Ibilex, Keflet, Keflex, Keforal, Keftab, Keftal, Lopilexin, Novo-Lexin, Ospexin, Zephalexin, Panixine Disperdose and Sporidex.
See also
External links
- MedlinePlus Drug Information: Cephalosporins (systemic) – information from USP DI Advice for the Patient
- FDA Drug Information PDF and Pharmacy Drug Information Insert.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Cephalosporin antibiotics
- Lilly